View Clinical Trials Below

Clinical Trials for Breast Cancer Treatments

Since 1989, breast cancer death rates have been decreasing thanks to advancements in treatment and earlier detection. At Regional Cancer Care Associates, we’re proud to be pioneers in the improvement of breast cancer treatments through our clinical trials. If you’re interest in enrolling in a breast cancer clinical trial, call RCCA today at 201-669-4706.

What Are Clinical Trials?

Before a new drug, medical strategy or device can be approved, it first must be evaluated for human use. This research process is called a clinical trial. As scientific studies, clinical trials are methodically designed to follow strict scientific standards. At the end of each trial, the data is used to determine if the new medical therapy is a safe and effective method for improving patient outcomes.

Why Should I Enroll in a Clinical Trial?

If you’ve been diagnosed with breast cancer, a clinical trial can give you access to the latest advancements and innovations in treatment methods and medications. In turn, you’ll participate in a research process that may one day help improve the quality of life for thousands of women and men around the world. It’s important to note that clinical trials are one of the final stages of a careful research process that’s been developed and tested in laboratories for a significant amount of time before being offered to humans. For your safety, all clinical trials are closely monitored by an institutional review board and scientific experts. Before agreeing to enroll in a breast cancer clinical trial, RCCA specialists require informed consent. This means that you’ll receive in-depth information about the trial, including treatments being used, its purpose and possible risks and benefits, prior to enrollment. And as far as cost of care goes, you won’t need to pay a penny. The company sponsoring the clinical trial will cover the bill, making clinical trials an affordable option for those diagnosed with breast cancer.

Breast Cancer Clinical Trials at RCCA

Your wellness and safety is placed above all else at RCCA. That’s why our clinical trials start with a personalized plan. To learn if you’re a good candidate for a breast cancer clinical trial, schedule an appointment with an RCCA cancer care physician today.
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Read more
Single Patient IND – Compassionate Use  Niraparib (MK-4827)
Single Patient IND – Compassionate Use Niraparib (MK-4827)

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Read more
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Read more
PALLAS: PALbociclib CoLlaborative Adjuvant Study:  A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Read more
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Read more
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Optimizing Personalized Care Using Economic Studies of Genomic Testing

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Read more
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women

Read more
Older Breast Cancer Patients: Risk for Cognitive Decline
Older Breast Cancer Patients: Risk for Cognitive Decline

Older Breast Cancer Patients: Risk for Cognitive Decline

Read more
Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers
Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Read more
An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease
An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Read more